8/10/2022 | 08-10-2022-Board | |
8/3/2022 | 08-03-2022-Board | |
7/15/2020 | 07-15-2020-Patent_Owner | |
5/29/2020 | 05-29-2020-Board | |
4/8/2020 | 04-08-2020-Patent_Owner | |
4/7/2020 | 04-07-2020-Petitioner | |
4/1/2020 | 04-01-2020-Board | |
3/25/2020 | 03-25-2020-Board | |
3/13/2020 | 03-13-2020-Petitioner | |
2/25/2020 | 02-25-2020-Board | |
2/24/2020 | 02-24-2020-Patent_Owner | |
2/24/2020 | 02-24-2020-Board | |
1/13/2020 | 01-13-2020-Patent_Owner | |
1/8/2020 | 01-08-2020-Petitioner | |
1/8/2020 | 01-08-2020-Patent_Owner | |
12/27/2019 | 12-27-2019-Petitioner | |
12/27/2019 | 12-27-2019-Patent_Owner | |
12/23/2019 | 12-23-2019-Petitioner | |
12/20/2019 | 12-20-2019-Patent_Owner | |
12/20/2019 | 12-20-2019-Petitioner | |
12/18/2019 | 12-18-2019-Petitioner | |
12/17/2019 | 12-17-2019-Board | |
12/16/2019 | 12-16-2019-Patent_Owner | |
12/9/2019 | 12-09-2019-Petitioner | |
12/5/2019 | 12-05-2019-Board | |
11/19/2019 | 11-19-2019-Petitioner | |
11/19/2019 | 11-19-2019-Patent_Owner | |
11/18/2019 | 11-18-2019-Petitioner | |
11/6/2019 | 11-06-2019-Petitioner | |
10/30/2019 | 10-30-2019-Patent_Owner | |
10/22/2019 | 10-22-2019-Petitioner | |
10/15/2019 | 10-15-2019-Patent_Owner | |
10/9/2019 | 10-09-2019-Petitioner | |
10/7/2019 | 10-07-2019-Patent_Owner | |
10/2/2019 | 10-02-2019-Patent_Owner | |
9/27/2019 | 09-27-2019-Petitioner | |
9/25/2019 | 09-25-2019-Patent_Owner | |
9/18/2019 | 09-18-2019-Petitioner | - Petitioner Exhibit 1044: Nat¿¿¿l. Diabetes Statistic Report 2017, ¿¿¿Estimates of Diabetes and Its
Burden in the United States, CDC, p.1-20
- Petitioner Exhibit 1045: Teresa L. Pearson, ¿¿¿Practical Aspects of Insulin Pen Devices¿¿¿, Journal of Diabetes Science and Technology, Vol. 4, Issue 3, May 2010, p.522-531
- Petitioner Exhibit 1046: Nancy J.V. Bohannon, ¿¿¿Insulin Delivery Using Pen Devices¿¿¿, Postgraduate Medicine, Vol. 106, No.5, Oct. 15, 1999, p. 57-68, ISSN: 0032-5481 (Print) 1941-9260 ¿¿¿ (Online) Journal homepage: https://www.tandfonline.com/loi/ipgm20
- Petitioner Exhibit 1047: Marilyn R. Graff, RN, CDE et al., ¿¿¿Assessment by Patients with Diabetes Mellitus of Two Insulin Pen...¿¿¿, Clinical Therapeutics, Vol. 20, No. 3, 1998, p.486-196
- Petitioner Exhibit 1048: Expert Declaration of William Curtis Biggs, M.D., FACE, ECNU in Support of Mylan-Pfizer Reply
- Petitioner Exhibit 1048: CORRECTED - Expert Declaration of William Curtis Biggs, M.D., FACE, ECNU in Support of Mylan-Pfizer Reply
- Petitioner Exhibit 1049: Curriculum Vitae of William Curtis Biggs, M.D., FACE, ECNU
- Petitioner Exhibit 1050: Slocum Deposition Exhibit 1050: Annotations of EX2107 (Declaration of Alexander Slocum Ph.D.)
- Petitioner Exhibit 1051: Slocum Deposition Exhibit 1051: Hand drawing of modified drive mechanism
- Petitioner Exhibit 1052: Slocum Deposition Exhibit 1052: Annotations of excerpted figures from EX2157
- Petitioner Exhibit 1053: Deposition of Alexander H. Slocum, Ph.D., August 27, 2019
- Petitioner Exhibit 1054: Deposition of Alexander H. Slocum, Ph.D., Vol II, August 28, 2019
- Petitioner Exhibit 1055: Deposition of Henry Grabowski, Ph.D., Sep. 5, 2019
- Petitioner Exhibit 1056: Deposition of Robin Goland, Sep. 10, 2019
- Petitioner Exhibit 1057: Benita Lee, MPH, ¿¿¿How Much Does Insulin Cost? Here¿¿¿s How 23 Brands Compare¿¿¿, Good RX, Aug. 23, 2019, pp. 1-11, https:www.goodrx.com/glo/how-much-does-insuling-cost,compare-brands/
- Petitioner Exhibit 1058: Certified English Translation of DE Patent 102 37 258A1, Dr. Roney Graf (Issued Mar. 18, 2004)
- Petitioner Exhibit 1059: M. Eledrisi, et al., ¿¿¿Twice-Daily Insulin Glargine for Patients with Uncontrolled Type 2 Diabetes Mellitus, Journal of Clinical & Translational Endocrinology 15 (2019), p. 35-36
- Petitioner Exhibit 1060: Declaration and c.v. of DeForrest McDuff, Ph.D.
- Petitioner Exhibit 1061: 2011 Orange Book (Excerpts)
- Petitioner Exhibit 1062: 2019 Orange Book (Excerpt ¿¿¿ ADA 132 of 263)
- Petitioner Exhibit 1063: 2011-02-09 - Sanofi SA Earnings Conference Call
- Petitioner Exhibit 1064: 2012-02-08 ¿¿¿ Sanofi SA Earnings Conference Call
- Petitioner Exhibit 1065: 2013-02-26 ¿¿¿ Sanofi SA at Citi Global HealthCare Conference
- Petitioner Exhibit 1066: 2014-02-06 ¿¿¿ Sanofi SA Earnings Conference Call
- Petitioner Exhibit 1067: Asamoah et al., ¿¿¿Insulin Pen ¿¿¿ The ¿¿¿iPod¿¿¿ for Insulin Delivery (Why Pen Wins Over Syringe)¿¿¿, J. of Diabetes Sci. and Technology, Vol. 2, Issue 2, March 2008, p.292-296
- Petitioner Exhibit 1068: Aventis 2002 20-F Form
- Petitioner Exhibit 1069: Aventis 2003 20-F Form
- Petitioner Exhibit 1070: Sanofi-Aventis 2006 20-F Form
- Petitioner Exhibit 1071: Correa, Carlos, ¿¿¿Ownership of Knowledge ¿¿¿ the Role of Patents in Pharmaceutical R&D¿¿¿, Round Table, Bulletin of World Health Org., 2004; 82; p.1-7
- Petitioner Exhibit 1072: Carter, Alan W., ¿¿¿Analysis of the Injection Force of Solostar¿¿ Compared with Other Disposable Insulin...¿¿¿, J. of Diabetes Sci. and Tech., Vol. 5, Issue 1, Jan. 2011, p. 156-157
- Petitioner Exhibit 1073: ¿¿¿About Diabetes¿¿¿, CDC Basics, p.1-2, https://www.cdc.gov/diabetes/bascis/diabetes
- Petitioner Exhibit 1074: David, J. et al. ¿¿¿Commercial Success: Economic Principles Applied to Patent Litigation¿¿¿, NERA Economic Consulting (copyrighted material), p. 159-160
- Petitioner Exhibit 1075: ¿¿¿Top Ten Tips on Writing Effectiveness Case Studies¿¿¿, By Design Business Association, May 23, 2016, p.1-5, https://www.dba.org.uk/review-top-ten-tips-on-writing-effectiveness-case-studies/
- Petitioner Exhibit 1076: DiMasi, J., et al. ¿¿¿Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs¿¿¿, J. of Health Economics 47 (2016), p. 20-33
- Petitioner Exhibit 1077: Grobowski, H., et al. ¿¿¿Returns on Research and Development for 1990s New Drug Introductions¿¿¿, Pharmacoeconomics 2002; 20 Suppl. 3: p. 11-29
- Petitioner Exhibit 1078: Pietrangelo, Ann ¿¿¿Levemir vs. Lantus: Similarities and Differences¿¿¿, Healthline, Oct. 19, 2016, p.1-14, https://www.healthline.com/health/deiabetes/levemir-lantus
- Petitioner Exhibit 1079: U.S. Patent 6,100,376, ¿¿¿A21, B30 Modified Insulin Derivatives having An Altered Action Profile¿¿¿, M. D¿¿rschug (issued Aug. 8, 2000)
- Petitioner Exhibit 1080: Lewcock, Anna, ¿¿¿Sanofi¿¿¿s SoloStar Hits US Market Despite Patent Suit¿¿¿, in-Pharma Technologist.com, Jul. 20, 2007, https://www.in-pharmatechnologist.com/Article/2007/07/31/Sanofi-s-SoloStar-hits-US-market-despite-patent-suit
- Petitioner Exhibit 1081: Lantus, ¿¿¿Get to Know the Lantus¿¿ SoloStar¿¿ Insulin Pen, p. 1-7, https://www.lantus.com/get-to-know-the-lantus-solostar-pen
- Petitioner Exhibit 1082: Lantus SoloStar Brochure: ¿¿¿High Blood Sugar, You¿¿¿re Going Down¿¿¿ (2012)
- Petitioner Exhibit 1083: Lantus SoloStar Brochure: ¿¿¿Your Guide to the Lantus SoloStar Insulin Pen¿¿¿ (2010)
- Petitioner Exhibit 1084: McDuff, et al., ¿¿¿Thinking Economically About Commercial Success¿¿¿, Landslide, March/April 2017, p. 37-40
- Petitioner Exhibit 1085: Nonaka, H., ¿¿¿FTO (Freedom to Operate) in the Pharmaceutical Industry¿¿¿, JSTOR, Pub. by Nomos Verlagsgesellschaft mbH (2018), p. 9-59
- Petitioner Exhibit 1086: Senate Comm. On Finance Ques. for the Record, ¿¿¿Drug Pricing in America¿¿¿: A Prescription for Change Part II, Questions for Olivier Brandicourt, CEO Sanofi, Feb. 26, 2019, p. 1-460
- Petitioner Exhibit 1087: S.G. Cowen, ¿¿¿Perspectives¿¿¿, Pharmaceutical Therapeutic Categories Outlook, Oct. 2001, p.134-148
- Petitioner Exhibit 1088: Cowen and Co., ¿¿¿Diabetes: Many New Drugs, But Insulin Still Dominant¿¿¿, Therapeutic Categories Outlook, Feb. 2015, p.477-491
- Petitioner Exhibit 1089: UBS Large Cap Pharmaceuticals Handbook, ¿¿¿U.S. Pharmaceuticals¿¿¿, Apr. 6, 2018, p.45-53
- Petitioner Exhibit 1090: Campbell, K., ¿¿¿Insulin Costs Are Skyrocketing. This is Why¿¿¿, U.S. New and World Report, Jun. 29, 2018, p.1-7
- Petitioner Exhibit 1091: U.S. Patent 5,656,722, ¿¿¿A21, B30, Modified Insulin Derivatives having An Altered Action Profile¿¿¿, M. D¿¿rschug (issued Aug. 12, 1997)
- Petitioner Exhibit 1092: U.S. Patent 7,476,652, ¿¿¿Acidic Insulin Preparations Having Improved Stability¿¿¿, Brunner-Schwarz (issued Jan. 13, 2009)
- Petitioner Exhibit 1093: U.S. Patent 7,713,930, ¿¿¿Acidic Insulin Preparations Having Improved Stability¿¿¿, Brunner-Schwarz (issued May 11, 2010
- Petitioner Exhibit 1094: WebMD, ¿¿¿Types of Insulin for Diabetes Treatment¿¿¿, p.1-7 https://www.webmd.com/diabetes/diabetes-types-insulin#1
- Petitioner Exhibit 1095: Reply Declaration of Karl Leinsing
|
9/3/2019 | 09-03-2019-Board | |
8/27/2019 | 08-27-2019-Petitioner | |
8/22/2019 | 08-22-2019-Petitioner | |
8/16/2019 | 08-16-2019-Patent_Owner | |
8/15/2019 | 08-15-2019-Board | |
8/14/2019 | 08-14-2019-Patent_Owner | |
8/13/2019 | 08-13-2019-Petitioner | |
8/8/2019 | 08-08-2019-Board | |
8/5/2019 | 08-05-2019-Board | |
7/29/2019 | 07-29-2019-Petitioner | |
7/19/2019 | 07-19-2019-Patent_Owner | |
7/17/2019 | 07-17-2019-Petitioner | |
7/2/2019 | 07-02-2019-Petitioner | |
6/25/2019 | 06-25-2019-Patent_Owner | - Patent Owner Exhibit 2100: Leinsing Deposition Exhibit 2100: Thomas van der Burg, Injection Force of SoloSTAR¿¿ Compared with Other Disposable Insulin Pen Devices at Constant Volume Flow Rates
- Patent Owner Exhibit 2101: Leinsing Deposition Exhibit 2101: Estelle Davis, et. al., An evaluation of prefilled insulin pens: a focuse on the Next Generation FlexPen¿¿
- Patent Owner Exhibit 2102: Leinsing Deposition Exhibit 2102: Hand drawings
- Patent Owner Exhibit 2103: Leinsing Deposition Exhibit 2103: Annotations of Figures 6-15 of Burroughs
- Patent Owner Exhibit 2104: Leinsing Deposition Exhibit 2104: Annotations of Figures 5-8 of the 486 Patent
- Patent Owner Exhibit 2105: Leinsing Deposition Exhibit 2105: Hand drawings
- Patent Owner Exhibit 2106: Leinsing Deposition exhibit 2106: Annotations of Figures 11 and 12 of Giambattista
- Patent Owner Exhibit 2107: Declaration of Alexander Slocum, Ph.D., Part One
- Patent Owner Exhibit 2107: Declaration of Alexander Slocum, Ph.D., Part Two
- Patent Owner Exhibit 2108: Curriculum Vitae of Alexander Slocum, Ph.D.
- Patent Owner Exhibit 2111: Declaration of Dr. Robin S. Goland
- Patent Owner Exhibit 2112: Curriculum Vitae of Dr. Robin S. Goland
- Patent Owner Exhibit 2113: Bradley M. Wright et al., A Review Of Insulin Pen Devices And Use In The Elderly Diabetic Population
- Patent Owner Exhibit 2114: Teresa L. Pearson, A-Practical-Review-of-Insulin-Pen-Devices
- Patent Owner Exhibit 2115: Arthritis & Diabetes, What do diabetes and arthritis have in common? Plenty.
- Patent Owner Exhibit 2116: Andreas Bode, Development of the SoloSTAR insulin pen device design verification and validation
- Patent Owner Exhibit 2117: Sanofi¿¿¿s Patented Pen animation
- Patent Owner Exhibit 2118: John Carter, Usability, Participant Acceptance, and Safety of a Prefilled Insulin Injection Device in a 3-Month Observational Survey in Everyday Clinical Practice in Australia
- Patent Owner Exhibit 2119: Sherwyn Schwartz, Correct Use of a New Reusable Insulin Injection Pen by Patients with Diabetes: A Design Validation Study
- Patent Owner Exhibit 2120: Estelle Davis, et. al., An evaluation of prefilled insulin pens: a focuse on the Next Generation FlexPen¿¿
- Patent Owner Exhibit 2121: DBA Design Effectiveness Awards 2009
- Patent Owner Exhibit 2122: SoloSTAR Disposable Pen Injector (The Grand Prix Oct. 22, 2009)
- Patent Owner Exhibit 2123: Arnd Friedrichs et al., Dose Accuracy and Injection Force of Different Insulin Glargine Pens
- Patent Owner Exhibit 2124: Stacey A. Seggelke et al., Effect of Glargine Insulin Delivery Method (Pen Device Versus Vial/Syringe) on Glycemic Control and Patient Preferences in Patients with Type 1 and Type 2 Diabetes
- Patent Owner Exhibit 2125: Julia Pfutzner et al., Evaluation of Dexterity in Insulin-Treated Patients with Type 1 and Type 2 Diabetes Mellitus
- Patent Owner Exhibit 2126: Jerome S. Fischer et al., United States Patient Preference and Usability for the New Disposable Insulin Device Solostar¿¿ versus Other Disposable Pens,
- Patent Owner Exhibit 2127: U.S. Provisional Patent Application 60/073820
- Patent Owner Exhibit 2128: Samita Garg et al., Insulin glargine and glulisine SoloSTAR pens for the treatment of diabetes
- Patent Owner Exhibit 2129: Nicolae Hancu et al., A Pan-European and Canadian Prospective Survey to Evaluate Patient Satisfaction with the SoloSTAR Insulin Injection Device in Type 1 and Type 2 Diabetes
- Patent Owner Exhibit 2130: Norbert Hermanns, Bernhard Kulzer & Thomas Haak, Dosing Accuracy with a Novel Pen Device (SoloSTAR) as Performed by Patients with Diabetes in a Clinical Setting
- Patent Owner Exhibit 2131: ISO 11608-1, Pen-injectors for medical use
- Patent Owner Exhibit 2132: Meike Krzywon et al., Study on the Dosing Accuracy of Commonly Used Disposable Insulin Pens
- Patent Owner Exhibit 2133: Lantus SoloSTAR Pen Guide
- Patent Owner Exhibit 2134: Arlan L. Rosenbloom, Limitation of Finger Joint Mobility in Diabetes Mellitus
- Patent Owner Exhibit 2135: Douglas Merritt et al., Dose Accuracy and Injection Force of Disposable Pens Delivering Pramlintide for the Treatment of Diabetes
- Patent Owner Exhibit 2136: Novo Nordisk Form 6-K (Feb. 9, 2009), Part Two
- Patent Owner Exhibit 2136: Novo Nordisk Form 6-K (Feb. 9, 2009), Part One
- Patent Owner Exhibit 2137: Novo Nordisk History, Part One
- Patent Owner Exhibit 2137: Novo Nordisk History, Part Two
- Patent Owner Exhibit 2138: W. Schady et al, Observations on Severe Ulnar Neuropathy in Diabetes
- Patent Owner Exhibit 2139: Alfred Penfornis & Kristian Horvat, Dose Accuracy Compariosn Between SoloSTAR and FlexPen at Three Different Dose Levels
- Patent Owner Exhibit 2140: Riccardo Perfetti, Reusable and Disposable Insulin Pens for the Treatment of Diabetes: Understanding the Global Differences in User Preference and an Evaluation of Inpatient Insulin Pen Use
- Patent Owner Exhibit 2141: John Shelmet et al., Preference and resource utilization in elderly patients: InnoLet versus vial/syringe
- Patent Owner Exhibit 2142: Prix Galien USA Announces 2009 Final Candidates
- Patent Owner Exhibit 2143: Thomas Haak et al., Comparison of Usability and Patient Preference for the New Disposable Insulin Device SoloStar Versus FlexPen, Lilly Disposable Pen, and a Prototype Pen: An Open-Label Study,
- Patent Owner Exhibit 2144: Alastair Clarke & Geralyn Spollett, Dose accuracy and injection force dynamics of a novel disposable insulin pen
- Patent Owner Exhibit 2145: US Lantus SoloSTAR Launch Book, 2007
- Patent Owner Exhibit 2146: Lantus COMPASS Study Report (Nov. 29, 2007), Part Two
- Patent Owner Exhibit 2146: Lantus COMPASS Study Report (Nov. 29, 2007), Part One
- Patent Owner Exhibit 2147: Steenfeldt-Jensen 5th Embodiment Animation
- Patent Owner Exhibit 2148: Steenfeldt-Jensen 1st Embodiment Animation
- Patent Owner Exhibit 2149: Steenfeldt-Jensen 2nd Embodiment Animation
- Patent Owner Exhibit 2150: Steenfeldt-Jensen 5th Embodiment Thread and Slot Animation
- Patent Owner Exhibit 2151: Steenfeldt-Jensen 5th Embodiment vs. Proposed Modification Animation
- Patent Owner Exhibit 2152: Steenfeldt-Jensen 5th Embodiment vs. Proposed Modification Collar Friction Animation
- Patent Owner Exhibit 2153: International Patent Application WO999038554A1
- Patent Owner Exhibit 2158: Geralyn Spollett, Insulin Devices, Addressing Barriers to Insulin Therapy With the Ideal Pen
- Patent Owner Exhibit 2159: Serpil Savas et al., The effects of the diabetes related soft tissue hand lesions and the reduced hand strength on functional disability of hand in type 2 diabetic patients
- Patent Owner Exhibit 2160: Jean-Louis Selam, Evolution of Diabetes Insulin Delivery Devices
- Patent Owner Exhibit 2161: SoloSTAR Principles of Operation
- Patent Owner Exhibit 2162: Sanofi Patent Drive Sleeve and Piston Rod Animation
- Patent Owner Exhibit 2163: Deposition of Karl R. Leinsing, dated June 3, 2019 for IPR2018-01675, -01676, -01678, -01680
- Patent Owner Exhibit 2164: Deposition of Karl R. Leinsing, dated June 4, 2019 for IPR2018-01675, -01676, -01678, -01680
- Patent Owner Exhibit 2165: Opinion and Order regarding Claim Construction, Sanofi-Aventis U.S. LLC v. Mylan, N.V., Civil Action No. 17-9105-SRC-SLW (D.N.J. May 9, 2019), Dkt. No. 319
- Patent Owner Exhibit 2166: Memorandum and Order regarding Claim Construction, Sanofi-Aventis U.S. LLC v. Merck, No. 16-812-RGA (D. Del. Jan. 12, 2018), Dkt. No. 192
- Patent Owner Exhibit 2167: Giambattista Animation (1)
- Patent Owner Exhibit 2168: Giambattista Animation (2)
- Patent Owner Exhibit 2169: U.S. Patent No. 4,648,872
- Patent Owner Exhibit 2170: U.S. Patent No. 4,747,824
- Patent Owner Exhibit 2171: U.S. Patent No. 6,248,093
- Patent Owner Exhibit 2172: Karl R. Leinsing Declaration in Hologic, Inc. v. Minerva Surgical, Inc., No. 15-1031 (D. Del. Jan. 26, 2018), Dkt. No. 309
- Patent Owner Exhibit 2173: Bruce A. Perkins, David Olaleye & Vera Bril, Carpal Tunnel Syndrome in Patients With Diabetic Polyneuropathy
- Patent Owner Exhibit 2174: Jefferson Becker et al., An evaluation of gender, obesity, age and diabetes mellitus as risk factors for carpal tunnel syndrome
- Patent Owner Exhibit 2175: A. Pfutzner et al., Prefilled insulin device with reduced injection force: patient perception and accuracy
- Patent Owner Exhibit 2176: Ercan Cetinus et al., Hand grip strength in patients with type 2 diabetes mellitus
- Patent Owner Exhibit 2177: Ragnhild I. Cederlund et al., Hand disorders, hand function, and activities of daily living in elderly men with type 2 diabetes
- Patent Owner Exhibit 2178: Shubha Gundmi et al., Hand dysfunction in type 2 diabetes mellitus: Systematic review with meta-analysis
- Patent Owner Exhibit 2179: Joule J. Li et al., Muscle grip strength predicts incident type 2 diabetes: Population-based cohort study
- Patent Owner Exhibit 2180: Considering Insulin Pens for Routine Hospital Use - (ISMP article)
- Patent Owner Exhibit 2181: Trigger Finger Overview (Mayo Clinic)
- Patent Owner Exhibit 2182: Bone and joint problems associated with diabetes (Mayo Clinic)
- Patent Owner Exhibit 2183: Peripheral Neuropathy (Mayo Clinic)
- Patent Owner Exhibit 2184: Charles E. Buban, A pen that seeks to improve diabetes care
- Patent Owner Exhibit 2185: Press Release: Sanofi-aventis¿¿¿ SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
- Patent Owner Exhibit 2186: Select Injectable Insulin Drugs Approved by the FDA in the U.S.
- Patent Owner Exhibit 2187: U.S. Dollar Sales of Lantus SoloSTAR
- Patent Owner Exhibit 2188: U.S. New Prescriptions of Lantus SoloSTAR
- Patent Owner Exhibit 2189: U.S. Total Prescriptions of Lantus SoloSTAR
- Patent Owner Exhibit 2190: U.S. Share of Sales by Drugs in the Lantus Franchise
- Patent Owner Exhibit 2191: Formulary Placement of Long-Acting Insulin Pen Products: Commercial Plans
- Patent Owner Exhibit 2192: Formulary Placement of Long-Acting Insulin Pen Products: Medicare Plans
- Patent Owner Exhibit 2193: Formulary Placement of Long-Acting Insulin Pen Products: Medicaid Plans
- Patent Owner Exhibit 2194: Formulary Placement of Long-Acting Insulin Pen Products in Healthcare Exchanges
- Patent Owner Exhibit 2195: U.S. Share of Long-Acting Pens Among All Pens
- Patent Owner Exhibit 2196: U.S. Dollar Sales of Long-Acting Pens
- Patent Owner Exhibit 2197: U.S. New Prescriptions of Long-Acting Pens
- Patent Owner Exhibit 2198: U.S. Total Prescriptions of Long-Acting Pens
- Patent Owner Exhibit 2199: U.S. Share of Long-Acting Pen Products
- Patent Owner Exhibit 2200: Yuzu Sato et al., Clinical Aspects of physical exercise for diabetes/metabolic syndrome
- Patent Owner Exhibit 2201: 2007 Good Design Award from The Chicago Athenaeum: Museum of Architecture and Design
- Patent Owner Exhibit 2203: U.S. Total Marketing Expenditure of Long Acting Insulin Franchises
- Patent Owner Exhibit 2204: U.S. Total Marketing Expenditures of Long-Acting Insulin Pens
- Patent Owner Exhibit 2205: U.S. Marketing-to-Sales Ratios of Select Injectable Insulin Drugs
- Patent Owner Exhibit 2206: M¿¿ller First Embodiment Animation
- Patent Owner Exhibit 2207: M¿¿ller Second Embodiment Animation
- Patent Owner Exhibit 2208: Press Release, Lantus / Apdira SoloSTAR help to improve patient satisfaction (June 27, 2011)
- Patent Owner Exhibit 2209: Henry Grabowski, John Vernon & Joseph A. DiMasi, Returns on Research and Development for 1990s New Drug Introductions
- Patent Owner Exhibit 2210: Julie M. Donohue, Marisa Cevasco & Meredith B. Rosenthal, A Decade of Direct-to-Consumer Advertising of Prescription Drugs
- Patent Owner Exhibit 2211: Collar Friction Model Demonstrator Animation
- Patent Owner Exhibit 2212: Excerpts from Ernest Rabinowicz, Friction And Wear of Materials, 2nd Edition
- Patent Owner Exhibit 2214: Excerpts from Alexander H. Slocum, Precision Machine Design
- Patent Owner Exhibit 2215: Collar Friction Model Demonstration 1
- Patent Owner Exhibit 2216: Collar Friction Model Demonstration 2
- Patent Owner Exhibit 2217: Collar Friction Model Demonstration 3
- Patent Owner Exhibit 2218: SoloSTAR Dial Inject Video
|
6/11/2019 | 06-11-2019-Patent_Owner | |
6/3/2019 | 06-03-2019-Patent_Owner | |
5/31/2019 | 05-31-2019-Patent_Owner | |
5/23/2019 | 05-23-2019-Patent_Owner | |
5/9/2019 | 05-09-2019-Board | |
4/16/2019 | 04-16-2019-Patent_Owner | |
4/16/2019 | 04-16-2019-Petitioner | |
4/2/2019 | 04-02-2019-Board | |
3/25/2019 | 03-25-2019-Petitioner | |
3/15/2019 | 03-15-2019-Board | |
2/28/2019 | 02-28-2019-Petitioner | |
2/20/2019 | 02-20-2019-Board | |
2/20/2019 | 02-20-2019-Patent_Owner | |
2/15/2019 | 02-15-2019-Petitioner | |
2/12/2019 | 02-12-2019-Patent_Owner | - Patent Owner Exhibit 2016: Defendants¿¿¿ Opposition to Plaintiffs¿¿¿ Motion to Stay dated Nov.
22, 2017, Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case
No. 1:17-cv-00181-IMK (N.D. W. Va.), Dkt. No. 44
- Patent Owner Exhibit 2017: Joint Proposed Discovery Plan dated Dec. 14, 2017, Sanofi-Aventis
U.S. LLC et al. v. Mylan N.V. et al., Case No. 2:17-cv-09105-SRCCLW
(D.N.J.)
- Patent Owner Exhibit 2018: Letter from A. Calmann to Judge Waldor dated Apr. 24, 2018,
Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case No. 2:17-
cv-09105-SRC-CLW (D.N.J.), Dkt. No. 90
- Patent Owner Exhibit 2019: Motion to Expedite Defendants¿¿¿ Motion Requesting an Expedited
Scheduling Conference dated Nov. 22, 2017 , Sanofi-Aventis U.S.
LLC et al. v. Mylan N.V. et al., Case No. 1:17-cv-00181-IMK (N.D.
W. Va.), Dkt. No. 46
- Patent Owner Exhibit 2020: Initial Planning Meeting Report and Discovery Proposals dated
Dec. 22, 2017, Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.,
Case No. 1:17-cv-00181-IMK (N.D. W. Va.), Dkt. No. 61
- Patent Owner Exhibit 2021: Transcript of Motion / Scheduling Conference dated Jan. 3, 2018,
Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case No. 1:17-
cv-00181-IMK (N.D. W. Va.), Dkt. No. 64
- Patent Owner Exhibit 2022: Excerpts from Transcript, Conference Call dated Aug. 2, 2018,
Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case No. 2:17-
cv-09105-SRC-CLW (D.N.J.)
- Patent Owner Exhibit 2023: Report of the Local Patent Rules Committee, Explanatory Notes for
2016 Amendments
- Patent Owner Exhibit 2024: Transcript, Conference Call for Case IPR2018-01675, -01676, -01678, -01680 (P.T.A.B. Feb. 5, 2019)
|
2/6/2019 | 02-06-2019-Patent_Owner | |
2/5/2019 | 02-05-2019-Board | |
1/30/2019 | 01-30-2019-Petitioner | |
1/23/2019 | 01-23-2019-Board | |
1/22/2019 | 01-22-2019-Petitioner | |
1/3/2019 | 01-03-2019-Patent_Owner | |
10/30/2018 | 10-30-2018-Petitioner | |
10/12/2018 | 10-12-2018-Petitioner | |
10/3/2018 | 10-03-2018-Board | |
9/27/2018 | 09-27-2018-Patent_Owner | |
9/13/2018 | 09-13-2018-Petitioner | |
9/10/2018 | 09-10-2018-Petitioner | Petitioner Power of Attorney 4: EXPUNGED- Petitioner Exhibit 1001: USP 8,679,069
- Petitioner Exhibit 1002: USP 8,603,044
- Petitioner Exhibit 1003: USP 8,992,486
- Petitioner Exhibit 1004: USP 9,526,844
- Petitioner Exhibit 1005: USP 9,604,008
- Petitioner Exhibit 1006: File History for U.S. Patent 8,679,069
- Petitioner Exhibit 1007: File History for U.S. Patent 8,603,044
- Petitioner Exhibit 1008: File History for U.S. Patent 8,992,486
- Petitioner Exhibit 1009: File History for U.S. Patent 9,526,844
- Petitioner Exhibit 1010: File History for U.S. Patent. 9,604,008
- Petitioner Exhibit 1011: Expert Declaration of Karl Leinsing MSME, PE in Support of Petition for Inter Partes Review of U.S. Patent Nos. 8,679,069; 8,603,044; 8,992,486; 9,526,844 and 9,604,008
- Petitioner Exhibit 1012: Curriculum Vitae of Karl Leinsing MSME,PE
- Petitioner Exhibit 1013: U.S. Patent 6,221,046 - A. Burroughs et al., ¿¿¿Recyclable Medication Dispensing Device¿¿¿ (issued Apr. 24, 2001)
- Petitioner Exhibit 1014: U.S. Patent 6,235,004 ¿¿¿ S. Steenfeldt-Jensen & S. Hansen, ¿¿¿Injection Syringe¿¿¿ (issued May 22, 2001)
- Petitioner Exhibit 1015: U.S. Patent Application US 2002/0053578 A1 ¿¿¿ C.S. M¿¿ller, ¿¿¿Injection Device¿¿¿ (pub¿¿¿d May 2, 2002)
- Petitioner Exhibit 1016: U.S. Patent 6,932,794 B2 ¿¿¿ L. Giambattista & A. Bendek, ¿¿¿Medication Delivery Pen¿¿¿ (issued Aug. 23, 2005)
- Petitioner Exhibit 1017: U.S. Patent 6,582,404 B1 ¿¿¿ P.C. Klitgaard et al., ¿¿¿Dose Setting Limiter¿¿¿ (issued June 24, 2003)
- Petitioner Exhibit 1018: File History for U.S. Patent 6,582,404
- Petitioner Exhibit 1019: Plaintiffs¿¿¿ Preliminary Claim Constructions and Preliminary Identification of Supporting Intrinsic and Extrinsic Evidence, Sanofi-Aventis U.S. LLC v. Mylan GmbH, No. 2:17-cv-09105 (D.N.J.) (filed Sep. 5 2018)
- Petitioner Exhibit 1020: U.S. Patent 4,865,591 ¿¿¿ B. Sams, ¿¿¿Measured Dose Dispensing Device¿¿¿ (issued Sep. 12, 1989)
- Petitioner Exhibit 1021: U.S. Patent 6,248,095 B1 ¿¿¿ L. Giambattista et al., ¿¿¿Low-cost Medication Delivery Pen¿¿¿ (issued June 19, 2001)
- Petitioner Exhibit 1022: U.S. Patent 6,921,995 B1 ¿¿¿ A.A. Bendek et al., ¿¿¿Medication Delivery Pen Having An Improved Clutch Assembly¿¿¿ (issued July 13, 1999)
- Petitioner Exhibit 1023: U.S. Patent 5,226,895 ¿¿¿ D.C. Harris, ¿¿¿Multiple Dose Injection Pen¿¿¿ (issued July 13, 1993)
- Petitioner Exhibit 1024: U.S. Patent 5,851,079 ¿¿¿ R.L. Horstman et al., ¿¿¿Simplified Unidirectional Twist-Up Dispensing Device With Incremental Dosing¿¿¿ (issued Dec. 22, 1998)
- Petitioner Exhibit 1025: Application as filed: U.S. Patent App. 14/946,203 ¿¿¿ R.F. Veasey, ¿¿¿Relating to a Pen-Type Injector¿¿¿ (filed Nov. 19, 2015)
- Petitioner Exhibit 1026: GB 0304822.0 ¿¿¿ ¿¿¿Improvements in and relating to a pen-type injector¿¿¿ (filed Mar. 3, 2003) (¿¿¿844 Priority Doc.)
- Petitioner Exhibit 1027: WO 99/38554 ¿¿¿ S.Steenfeldt-Jensen & S.Hansen, ¿¿¿An Injection Syringe¿¿¿ (pub¿¿¿d Aug. 5, 1999) (Steenfeldt-Jensen PCT)
- Petitioner Exhibit 1028: Mylan GmbH and Biocon¿¿¿s Preliminary Claim Constructions and Supporting Evidence Pursuant to L. Pat. R. 4.2, Sanofi-Aventis U.S., LLC v. Mylan N.V., C.A. No. 17-cv-09105 (filed Sep. 5, 2018)
- Petitioner Exhibit 1029: Memorandum Opinion, Sanofi-Aventis U.S. LLC v. Merck Sharp & Dohme Corp., No. 16-cv-812 (filed Jan. 12, 2018)
- Petitioner Exhibit 1030: Memorandum Opinion, Sanofi -Aventis U.S. LLC v. Eli Lily and Co., No. 14-cv-113 (filed Jan. 20, 2015)
- Petitioner Exhibit 1031: N. Sclater & N.P. Chironis, Mechanisms & Mechanical Devices Sourcebook 191-95, ¿¿¿Twenty Screw Devices¿¿¿ (3d ed., July 2, 2001)
- Petitioner Exhibit 1032: EP 0 608 343 B1 ¿¿¿ L. Petersen & N.-A. Hansen, ¿¿¿Large Dose Pen¿¿¿ (pub¿¿¿d Oct. 18, 1991)
- Petitioner Exhibit 1033: A.G. Erdman &G.N. Sandor, ¿¿¿ Mechanical Advantage¿¿¿, ¿¿3.7 in 1 Mechanism Design: Analysis and Synthesis (1984)
- Petitioner Exhibit 1034: WO 01/83008 ¿¿¿ S. Hansen & T.D. Miller., ¿¿¿An Injection Device, A Preassembled Dose Setting And Injection Mechanism For An Injection Device, And A Method Of Assembling An Injection Device¿¿¿ (pub¿¿¿d Nov. 8, 2001)
- Petitioner Exhibit 1035: K.J. Lipska et al., Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits ... 320 J. Am. Med. Ass¿¿¿n 53-62 (2018).
|